Merck buys Idenix

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

In an all-cash deal, Merck (MRK) acquires Hep C drug maker Idenix Pharmaceuticals (IDIX) for $24.50/share ($3.85B). The company has an attractive portfolio of Hep C product candidates based on nucleotide/nucleoside chemistry and prodrug technologies.